KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024)

Recursion Pharmaceuticals' Acquisitions history spans 2 years, with the latest figure at -$277.1 million for Q4 2024.

  • For Q4 2024, Acquisitions fell 390387.32% year-over-year to -$277.1 million; the TTM value through Dec 2024 reached -$277.0 million, down 390287.32%, while the annual FY2024 figure was -$277.1 million, 14927.33% down from the prior year.
  • Acquisitions reached -$277.1 million in Q4 2024 per RXRX's latest filing, down from $71000.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $71000.0 in Q4 2023 to a low of -$277.1 million in Q4 2024.